Form 8-K





Washington, D.C. 20549



Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 27, 2008


(Exact name of registrant as specified in its charter)


Delaware   0-25317   33-0373077

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)


5791 Van Allen Way, Carlsbad, CA   92008
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (760) 603-7200

1600 Faraday Avenue, Carlsbad, CA 92008

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Section 1 - Registrant’s Business and Operations


Item 1.01 Entry into a Material Definitive Agreement

Chief Executive Officer Compensation. On February 27, 2008, at a meeting of the Board of Directors of the Company, the independent members of the Board of Directors approved an increase in the base salary of Mr. Gregory T. Lucier, the Company’s Chief Executive Officer. Effective as of February 27, 2008, and retroactive to January 1, 2008, Mr. Lucier’s new base salary was set at $975,000.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


    Invitrogen Corporation
Date March 4, 2008     /s/ John A. Cottingham
    John A. Cottingham
    Sr. Vice President, General Counsel and Secretary